Fluicell

Fluicell is a Swedish biotechnology startup dedicated to revolutionizing disease treatment through innovative tissue solutions for regenerative medicine and drug screening. The company's groundbreaking Nexocyte platform, developed over two decades of disruptive R&D, introduces novel approaches to combat serious diseases by leveraging precision-engineered biological tissues. These transplantable tissues hold promise in addressing irreparable tissue damage associated with cardiac, pulmonary, metabolic, kidney, and other ailments, with a primary focus on developing solutions for type 1 diabetes. In addition to its therapeutic pursuits, Fluicell collaborates with leading partners to enhance drug-screening capabilities, aiming to facilitate the development of transformative medications. The company secured a kr4.00M Post-IPO Equity investment on 16 October 2020, with support from Pensys, Johan Stein, and Strategic Wisdom Nordic. Fluicell's innovative approach and potential to address unmet medical needs position it as a noteworthy player in the biotechnology, healthcare, and pharmaceutical industries.